Joes Future Food, a leading company in the field of cell-cultured meat in China, recently announced the successful completion of a Series A+ funding round, raising millions of RMB.

Following the strong recognition from renowned investment firms in 2020 and 2021, Joes Future Food once again received full support from top-tier investment institutions in this round. The infusion of funds will aid the establishment of a pilot plant with a capacity of thousands of liters, enabling the company to launch market-competitive cell-cultured meat products by 2024-2025. Targeting the multi-million-ton meat consumption market, Joes Future Food aims to reshape the landscape of meat protein supply.

Founded in December 2019, Joes Future Food is a pioneer in the field of cell-cultured meat in China. The company's founding team has dedicated years of research and development in the domain, successfully breaking the foreign technological monopoly through independent innovation. Leveraging their capabilities and resources across the entire value chain, Joes Future Food has achieved success in fundamental research, industrialization, and regulatory policy research. Currently, Joes Future Food is the only domestic company capable of achieving scale-up production of cell-cultured meat at the hundred-liter level.

Joes Future Food has made significant breakthroughs in various aspects of the cell-cultured meat industry and has formulated clear strategies for scaling up and reducing costs. They have developed proprietary culture media with multiple generations of intellectual property protection, leading to a substantial reduction in cell proliferation and differentiation costs. Through relentless innovation, Joes Future Food has successfully entered the small-scale pilot production stage, driving the commercialization process of cell-cultured meat.

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.